A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This was a Phase 2, open-label, multicenter study evaluating the preliminary efficacy and
safety of venetoclax (ABT-199) administered orally in participants with acute myelogenous
leukemia (AML).